Our findings reveal the potential of pharmacologically and selectively increasing IRE1/XBP1s signaling using compounds like IXA4 to stimulate a beneficial reprogramming in several tissues to mitigate obesity-driven metabolic dysfunction. The gene discussed is ERN1; the disease is obesity due to melanocortin 4 receptor deficiency.